Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Assets Average (2017 - 2025)

Protagonist Therapeutics' Assets Average history spans 9 years, with the latest figure at $684.9 million for Q4 2025.

  • For Q4 2025, Assets Average rose 1.58% year-over-year to $684.9 million; the TTM value through Dec 2025 reached $684.9 million, up 1.58%, while the annual FY2025 figure was $706.5 million, 28.13% up from the prior year.
  • Assets Average for Q4 2025 was $684.9 million at Protagonist Therapeutics, down from $709.8 million in the prior quarter.
  • Across five years, Assets Average topped out at $743.4 million in Q1 2025 and bottomed at $243.9 million in Q1 2023.
  • The 5-year median for Assets Average is $355.8 million (2021), against an average of $455.6 million.
  • The largest annual shift saw Assets Average decreased 29.91% in 2023 before it skyrocketed 122.0% in 2024.
  • A 5-year view of Assets Average shows it stood at $360.4 million in 2021, then decreased by 26.46% to $265.1 million in 2022, then increased by 29.78% to $344.0 million in 2023, then skyrocketed by 96.02% to $674.3 million in 2024, then rose by 1.58% to $684.9 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Assets Average are $684.9 million (Q4 2025), $709.8 million (Q3 2025), and $730.1 million (Q2 2025).